Abstract
Transmissible interfering dengue particles (DENV–TIPs) are engineered dengue virus mutants which are defective and can replicate only with the help of dengue wild–type virus (DENV). In vitro studies have found that when DENV–TIPs and DENV coinfect a cell, they compete for viral genomes and cell proteins for replication and packaging, and DENV–TIPs outperform DENV in this process. Thus, it is hypothesised that DENV–TIPs may be used as a novel therapeutic agent. However, the effectiveness of DENV–TIPs as an antiviral agent is yet to be explored at an epidemiological scale. We present a mathematical model for the replication of DENV and DENV–TIPs as they interact with human host cells, accounting for the effectiveness of DENV–TIPs in blocking DENV from coinfected cells. We fit the model to sequentially measured plasma viral titre data from primary and secondary dengue serotype 1 infected patients in Vietnam. We show that variation in initial DENV load is sufficient to recreate the observed variation between patients. Parameter estimates, differing in primary and secondary infections, do not confirm a significant difference between these two types of infection. We use our model to investigate the potential impact of DENV–TIPs as an antiviral agent. We conclude that, when the effectiveness of DENV–TIPs in inhibiting DENV from coinfected cells is at least 80%, a dose as high as $10^{12}$ copies per millilitre of blood is required to reduce duration of infection and peak DENV serotype 1 infection level at any time point of infection. This work provides a quantitative understanding of the relationship between DENV–TIPs levels and their efficiency in clearing dengue viral infection. It will guide future development of mechanistic models of how DENV–TIPs might contribute as an antiviral agent in limiting natural dengue infection.
Introduction
Dengue virus (DENV) remains a critical global health challenge, with approximately 400 million infections occurring annually. Despite its prevalence, universally effective vaccines and antiviral treatments remain elusive. Traditional control methods, such as vector management or the introduction of Wolbachia bacteria, face significant hurdles in terms of cost and scalability.
This study explores an innovative therapeutic strategy: Transmissible Interfering Particles (TIPs). TIPs are engineered, defective versions of the dengue virus that lack the genetic machinery to replicate independently. Instead, they act as "parasites" to the wild-type virus, co-opting viral proteins and cellular resources to replicate. Because TIPs are genetically streamlined, they can theoretically outcompete DENV within a host, reducing viral load and disease severity. While this interference has been demonstrated in vitro, its clinical potential within human hosts requires rigorous quantitative evaluation.
Methods
The researchers developed a within-host mathematical model using a system of six Ordinary Differential Equations (ODEs). This model tracks the interactions between uninfected cells, cells infected solely by DENV, cells infected solely by TIPs, and "coinfected" cells containing both. It also accounts for the free-floating populations of both DENV and TIPs.
To calibrate the model, the authors employed Bayesian parameter estimation using a Markov Chain Monte Carlo (MCMC) algorithm implemented in the Stan programming language. Two primary modeling approaches were compared:
- Model A: Assumed biological parameters (e.g., viral replication and clearance rates) were uniform across all patients.
- Model B: Allowed parameters to vary between primary (first-time) and secondary (repeat) infections to account for potential Antibody-Dependent Enhancement (ADE).
Clinical Data and Model Calibration
The study utilized a high-quality clinical dataset from Ho Chi Minh City, Vietnam, focusing on 67 adult patients specifically infected with Dengue Serotype 1 (DENV1). This cohort included 25 primary and 42 secondary infections, with daily plasma viral titre measurements recorded for up to five days post-fever onset.
The longitudinal data (Figure 1) highlights the significant variation in viral load trajectories among patients. Interestingly, the model selection process favored the simpler Model A. This suggests that the fundamental within-host dynamics of DENV1 are remarkably consistent across different infection types once the initial viral load is accounted for.
Key Findings
The Role of Initial Viral Load ($V_0$)
A major insight from the model is that the variation in the initial amount of virus received (the inoculum, $V_0$) is sufficient to explain the diverse viral load patterns observed in patients. This implies that the severity of an individual's infection may be heavily influenced by the starting dose rather than just inherent biological differences between hosts.
Primary vs. Secondary Infection Dynamics
Contrary to expectations based on the Antibody-Dependent Enhancement (ADE) theory, the model found no statistically significant difference in biological parameters between primary and secondary infections. However, the authors note that the data was primarily collected after the viral peak, which may obscure differences occurring during the early expansion phase of the infection.
Thresholds for TIP Efficacy
The model identified a critical "tipping point" for therapeutic success. For TIPs to effectively reduce the peak viral load and infection duration, they must achieve at least 80% effectiveness in inhibiting wild-type replication within coinfected cells. If effectiveness falls below this threshold, TIPs could paradoxically extend the duration of infection by keeping host cells viable longer, thereby allowing for sustained viral production.
Therapeutic Implications and Results
The simulations indicate that a substantial dose of approximately $10^{12}$ TIP copies per milliliter of blood is required to achieve a meaningful clinical impact. While administering TIPs at the onset of symptoms (approximately four days before the fever peak) is most effective, the model suggests they can still provide benefits even if administered shortly after the viral peak.
Limitations and Future Directions
While providing a quantitative framework for TIP therapy, the model includes several simplifications:
- Immune Response: The current model does not explicitly incorporate the complex dynamics of the innate and adaptive immune systems (e.g., T-cells and antibodies), which are vital for viral clearance.
- Parameter Constancy: The effectiveness of TIPs was modeled as a constant, whereas it likely varies with particle concentration in a real biological environment.
- Data Constraints: The lack of data from the very early stages of infection (pre-symptomatic) limits the precision of the model's early-phase predictions.
Future research will aim to integrate these TIP models with more detailed immune system dynamics and validate the findings against other dengue serotypes (DENV2-4) to ensure broader therapeutic applicability.
Summary updated